Product Pipeline

Pain & Inflammation

Chronic pain affects over 86 million American adults andover 1.5 billion patients worldwide. Arthritis affects 46 million Americans and costs the US over $12 billion annually. Nonsteroidal anti-inflammatory drugs (NSAIDs) are the oldest, most successful class of drugs and continue to be the primary treatment for pain and inflammation (73 million prescriptions and more than 30 billion OTC tablets were sold in 2005 in the US). However, NSAIDs cause serious side effects including gastrointestinal (GI) toxicity, cardiovascular events, hypertension and renal failure. Serious GI ulcers afflict 10-25% of chronically treated NSAID arthritis patients and at least 10-20% of patients suffer from dyspepsia (upset stomach) or other nuisance side effects. NSAID-induced upper GI adverse events result in 107,000 hospitalizations, 43% of drug-related emergency visits and 16,500 deaths per year (15th most common cause of death in the US, more than AIDS).

Based on preclinical studies conducted by Sagene using proprietary combinations with NSAIDS protects against NSAID-induced GI toxicity by increasing NO, preventing neutrophil adherence and increasing blood flow.